Personal tools

Coexpression cluster:C169

From FANTOM5_SSTAR

Revision as of 13:40, 26 November 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C169_hereditary_adult_gall_lymphangiectasia_chronic_b_choriocarcinoma



Phase1 CAGE Peaks

Hg19::chr10:129780311..129780325,+p@chr10:129780311..129780325
+
Hg19::chr11:12017002..12017006,-p@chr11:12017002..12017006
-
Hg19::chr11:45077600..45077605,-p@chr11:45077600..45077605
-
Hg19::chr12:101114061..101114068,+p@chr12:101114061..101114068
+
Hg19::chr12:111115637..111115643,-p@chr12:111115637..111115643
-
Hg19::chr12:129886232..129886236,+p@chr12:129886232..129886236
+
Hg19::chr12:54430774..54430776,+p@chr12:54430774..54430776
+
Hg19::chr12:54430838..54430849,+p@chr12:54430838..54430849
+
Hg19::chr12:54430878..54430894,+p@chr12:54430878..54430894
+
Hg19::chr13:36788658..36788703,-p2@CCDC169-SOHLH2
p2@SOHLH2
Hg19::chr13:36788718..36788729,-p3@CCDC169-SOHLH2
p3@SOHLH2
Hg19::chr13:90031692..90031701,-p@chr13:90031692..90031701
-
Hg19::chr13:90054694..90054707,+p@chr13:90054694..90054707
+
Hg19::chr13:98832731..98832745,+p@chr13:98832731..98832745
+
Hg19::chr14:100485632..100485641,-p@chr14:100485632..100485641
-
Hg19::chr14:100485707..100485728,-p@chr14:100485707..100485728
-
Hg19::chr14:100485712..100485727,+p14@EVL
Hg19::chr14:100485738..100485745,+p37@EVL
Hg19::chr14:106347250..106347263,-p@chr14:106347250..106347263
-
Hg19::chr14:106453005..106453010,-p1@HM995871
Hg19::chr14:25495787..25495796,-p@chr14:25495787..25495796
-
Hg19::chr14:72944734..72944763,+p@chr14:72944734..72944763
+
Hg19::chr14:93336950..93336968,-p@chr14:93336950..93336968
-
Hg19::chr15:23841916..23841926,-p@chr15:23841916..23841926
-
Hg19::chr15:52404898..52404917,-p4@BCL2L10
Hg19::chr15:52404921..52404940,-p2@BCL2L10
Hg19::chr15:83368645..83368652,-p@chr15:83368645..83368652
-
Hg19::chr15:96537325..96537333,-p@chr15:96537325..96537333
-
Hg19::chr15:96539848..96539851,-p@chr15:96539848..96539851
-
Hg19::chr15:99539699..99539703,+p@chr15:99539699..99539703
+
Hg19::chr16:55880765..55880779,-p@chr16:55880765..55880779
-
Hg19::chr17:11711799..11711827,-p@chr17:11711799..11711827
-
Hg19::chr17:21251902..21251907,-p@chr17:21251902..21251907
-
Hg19::chr17:34206860..34206865,-p@chr17:34206860..34206865
-
Hg19::chr17:51127122..51127127,-p@chr17:51127122..51127127
-
Hg19::chr17:51147371..51147377,+p@chr17:51147371..51147377
+
Hg19::chr17:59322535..59322541,-p@chr17:59322535..59322541
-
Hg19::chr17:59322564..59322600,+p5@BCAS3
Hg19::chr17:60536002..60536040,+p4@TLK2
Hg19::chr17:70016724..70016733,-p@chr17:70016724..70016733
-
Hg19::chr18:56320706..56320709,+p@chr18:56320706..56320709
+
Hg19::chr18:59518131..59518142,-p@chr18:59518131..59518142
-
Hg19::chr18:59518164..59518170,-p@chr18:59518164..59518170
-
Hg19::chr18:60662408..60662414,+p@chr18:60662408..60662414
+
Hg19::chr19:28913175..28913210,+p@chr19:28913175..28913210
+
Hg19::chr1:15482761..15482763,-p@chr1:15482761..15482763
-
Hg19::chr1:15563005..15563040,+p@chr1:15563005..15563040
+
Hg19::chr1:15563067..15563079,+p@chr1:15563067..15563079
+
Hg19::chr1:159267075..159267096,+p@chr1:159267075..159267096
+
Hg19::chr1:210573062..210573064,-p@chr1:210573062..210573064
-
Hg19::chr1:229504069..229504072,-p@chr1:229504069..229504072
-
Hg19::chr1:24581338..24581346,-p1@uc001biw.2
Hg19::chr1:24581364..24581374,-p@chr1:24581364..24581374
-
Hg19::chr1:25876348..25876361,+p5@LDLRAP1
Hg19::chr1:25876368..25876381,+p6@LDLRAP1
Hg19::chr1:25876405..25876417,+p8@LDLRAP1
Hg19::chr20:25475219..25475229,-p@chr20:25475219..25475229
-
Hg19::chr20:56058118..56058120,-p@chr20:56058118..56058120
-
Hg19::chr20:56058449..56058484,+p@chr20:56058449..56058484
+
Hg19::chr20:59009589..59009592,+p@chr20:59009589..59009592
+
Hg19::chr22:25075039..25075064,+p@chr22:25075039..25075064
+
Hg19::chr22:25075096..25075120,+p@chr22:25075096..25075120
+
Hg19::chr22:33206569..33206577,+p@chr22:33206569..33206577
+
Hg19::chr22:33206603..33206608,+p@chr22:33206603..33206608
+
Hg19::chr22:33206615..33206622,+p@chr22:33206615..33206622
+
Hg19::chr22:33221188..33221202,+p@chr22:33221188..33221202
+
Hg19::chr22:47883693..47883699,-p@chr22:47883693..47883699
-
Hg19::chr2:135361356..135361362,-p@chr2:135361356..135361362
-
Hg19::chr2:173750319..173750340,-p@chr2:173750319..173750340
-
Hg19::chr2:206489395..206489396,-p@chr2:206489395..206489396
-
Hg19::chr2:45490454..45490486,-p@chr2:45490454..45490486
-
Hg19::chr3:106921810..106921817,-p@chr3:106921810..106921817
-
Hg19::chr3:106921835..106921857,-p@chr3:106921835..106921857
-
Hg19::chr3:128579995..128580003,+p@chr3:128579995..128580003
+
Hg19::chr3:133185639..133185654,+p@chr3:133185639..133185654
+
Hg19::chr3:184113225..184113231,-p@chr3:184113225..184113231
-
Hg19::chr3:25449881..25449891,-p@chr3:25449881..25449891
-
Hg19::chr4:170719812..170719813,+p@chr4:170719812..170719813
+
Hg19::chr5:132587921..132587932,-p5@FSTL4
Hg19::chr5:132587961..132587985,-p3@FSTL4
Hg19::chr6:144724237..144724255,+p@chr6:144724237..144724255
+
Hg19::chr6:32582541..32582590,-p@chr6:32582541..32582590
-
Hg19::chr7:140980284..140980289,+p@chr7:140980284..140980289
+
Hg19::chr7:22136603..22136614,+p@chr7:22136603..22136614
+
Hg19::chr7:69393144..69393149,-p@chr7:69393144..69393149
-
Hg19::chr7:69393274..69393286,+p@chr7:69393274..69393286
+
Hg19::chr7:70419611..70419618,+p@chr7:70419611..70419618
+
Hg19::chr8:105291143..105291166,-p@chr8:105291143..105291166
-
Hg19::chr8:12898422..12898427,-p@chr8:12898422..12898427
-
Hg19::chr8:12999595..12999600,+p@chr8:12999595..12999600
+
Hg19::chr8:13199276..13199284,+p@chr8:13199276..13199284
+
Hg19::chr8:13199316..13199325,+p@chr8:13199316..13199325
+
Hg19::chr8:13526697..13526704,+p@chr8:13526697..13526704
+
Hg19::chr8:138082720..138082726,-p@chr8:138082720..138082726
-
Hg19::chr8:22559267..22559271,-p@chr8:22559267..22559271
-
Hg19::chr8:86174690..86174727,+p@chr8:86174690..86174727
+
Hg19::chr9:124116019..124116044,-p@chr9:124116019..124116044
-
Hg19::chr9:124116047..124116052,-p@chr9:124116047..124116052
-
Hg19::chr9:124632999..124633011,-p@chr9:124632999..124633011
-
Hg19::chr9:35194941..35194952,-p@chr9:35194941..35194952
-
Hg19::chr9:80847589..80847596,-p@chr9:80847589..80847596
-
Hg19::chrX:46811494..46811522,-p@chrX:46811494..46811522
-
Hg19::chrX:71093307..71093345,-p@chrX:71093307..71093345
-


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0016323basolateral plasma membrane0.0201253396018479
GO:0001672regulation of chromatin assembly or disassembly0.0201253396018479
GO:0015460transport accessory protein activity0.0201253396018479
GO:0048260positive regulation of receptor-mediated endocytosis0.0201253396018479
GO:0030121AP-1 adaptor complex0.0201253396018479
GO:0030669clathrin-coated endocytic vesicle membrane0.0201253396018479
GO:0030128clathrin coat of endocytic vesicle0.0201253396018479
GO:0030122AP-2 adaptor complex0.0201253396018479
GO:0005522profilin binding0.0201253396018479
GO:0001784phosphotyrosine binding0.0201253396018479
GO:0045309protein phosphorylated amino acid binding0.0201253396018479
GO:0030666endocytic vesicle membrane0.0201253396018479
GO:0045334clathrin-coated endocytic vesicle0.0201253396018479
GO:0048259regulation of receptor-mediated endocytosis0.0201253396018479
GO:0051219phosphoprotein binding0.0268120729752947
GO:0030276clathrin binding0.0268120729752947
GO:0043393regulation of protein binding0.0268120729752947
GO:0030132clathrin coat of coated pit0.0268120729752947
GO:0042632cholesterol homeostasis0.0268120729752947
GO:0055092sterol homeostasis0.0268120729752947
GO:0045178basal part of cell0.0268120729752947
GO:0009925basal plasma membrane0.0268120729752947
GO:0030130clathrin coat of trans-Golgi network vesicle0.0268120729752947
GO:0055088lipid homeostasis0.0268120729752947
GO:0045807positive regulation of endocytosis0.0268120729752947
GO:0012510trans-Golgi network transport vesicle membrane0.0268120729752947
GO:0030159receptor signaling complex scaffold activity0.0268120729752947
GO:0017124SH3 domain binding0.0277325453196628
GO:0032947protein complex scaffold0.0277325453196628
GO:0030125clathrin vesicle coat0.0280204918071434
GO:0030139endocytic vesicle0.0280204918071434
GO:0005829cytosol0.0280204918071434
GO:0030665clathrin coated vesicle membrane0.0280204918071434
GO:0051098regulation of binding0.0330964323601507
GO:0030140trans-Golgi network transport vesicle0.0332966133538596
GO:0030658transport vesicle membrane0.0338330086151013
GO:0065009regulation of a molecular function0.0338330086151013
GO:0030660Golgi-associated vesicle membrane0.0338330086151013
GO:0030100regulation of endocytosis0.0341451676617017
GO:0005925focal adhesion0.0341451676617017
GO:0007292female gamete generation0.03428961072765
GO:0005924cell-substrate adherens junction0.0350245552621578
GO:0051050positive regulation of transport0.0350245552621578
GO:0030027lamellipodium0.0350245552621578
GO:0030055cell-matrix junction0.0350245552621578
GO:0007015actin filament organization0.0350245552621578
GO:0006898receptor-mediated endocytosis0.0350245552621578
GO:0005905coated pit0.0359625052134099
GO:0006919caspase activation0.0376780663092173
GO:0051052regulation of DNA metabolic process0.0378523782391324
GO:0005769early endosome0.0378523782391324
GO:0030120vesicle coat0.0378523782391324
GO:0043280positive regulation of caspase activity0.0378523782391324
GO:0030662coated vesicle membrane0.0378916483779762
GO:0030131clathrin adaptor complex0.0380005712279603
GO:0005912adherens junction0.0380005712279603
GO:0030119AP-type membrane coat adaptor complex0.0380005712279603
GO:0043281regulation of caspase activity0.0414500800115022
GO:0008154actin polymerization and/or depolymerization0.0414500800115022
GO:0030133transport vesicle0.0420894203107372
GO:0030118clathrin coat0.0433612596610362
GO:0005798Golgi-associated vesicle0.0445912181473384
GO:0031252leading edge0.04507972218143
GO:0012505endomembrane system0.04507972218143
GO:0008022protein C-terminus binding0.0455984987589061
GO:0051345positive regulation of hydrolase activity0.0461145460520442
GO:0008203cholesterol metabolic process0.0466148382190784
GO:0043229intracellular organelle0.0466526491276922
GO:0043226organelle0.0466526491276922
GO:0016043cellular component organization and biogenesis0.0467027924574183



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br><br>disease_data<br>

Cell Type
Ontology termp-valuen
lymphocyte of B lineage1.01e-0924
pro-B cell1.01e-0924
Disease
Ontology termp-valuen
anemia5.42e-1951
hematopoietic system disease1.55e-982
cardiovascular system disease3.10e-504
lymphoma3.81e-2110


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)

TF#promotersEnrichmentp-valueq-value
EBF1#1879221.902352141985610.002192958218885880.0126403423711144



Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C169&oldid=2556500"